LONDON, August 11, 2017 /PRNewswire/ --
Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others
The global diabetes drugs market was valued at $49.26bn in 2016 and is projected to grow at a CAGR of 6.1% in the first half of the forecast period.to reach global revenue of $66.29bn in 2021. The largest drug class in the market in 2016 was human insulin and analogues. This drug class held 55% share of the global diabetes drugs market in 2016.
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
How this report will benefit you:
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand-new 262 page report you will receive 75 tables and 141 figures - all unavailable elsewhere.
The 262-page report provides clear detailed insight into the global diabetes drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope:
• Global Diabetes Drugs Market forecasts from 2017-2027
• Provides qualitative analysis and forecast of the human insulins and analogues submarket for the period 2017-2027:
• Lantus (insulin aspart)
• NovoLog (insulin aspart)
• Humalog (insulin lispro)
• Levemir (insulin detemir)
• Human Insulins by Novo Nordisk
• NovoMix (insulin aspart)
• Humulin (insulin isophane)
• Provides qualitative analysis and forecast of the dipeptidyl peptidase-4 inhibitors (DPP-4) submarket for the period 2017-2027:
• Januvia (sitagliptin)
• Janumet (sitagliptin and metformin)
• Galvus (vidagliptin)
• Onglyza (saxagluiptin)
• Nesina (alogliptin)
• Tradjenta (linagliptin)
• Provides qualitative analysis and forecast of the sulfonylurea submarket for the period 2017-2027:
• Diamicron (gliclazide)
• Amaryl (glimepiride)
• Glucotrol (glipizide)
• Provides qualitative analysis and forecast of the glucagon-like peptide-1 (GLP-1) receptor agonists submarket for the period 2017-2027:
• Victoza (liraglutide)
• Byetta (exenatide)
• Bydureon (exenatide)
• Provides qualitative analysis and forecast of the alpha-glucosidase class submarket for the period 2017-2027:
• Glucobay (acarbose)
• Basen (voglibose)
• Glyset (miglitol)
• Provides qualitative analysis and forecast of the meglitinides submarket for the period 2017-2027:
• Prandin (repaglinide)
• Sarlix (nateglinide)
• Glufast (acarbose).
• Provides qualitative analysis and forecast of the sodium-glucose co-transporter 2 (SGLT2) inhibitors submarket for the period 2017-2027:
• Invokana (canagliflozin)
• Forxiga (dapagliflozin)
• Jardiance (empaglifozin)
• Provides qualitative analysis and forecast of the biguanides submarket for the period 2017-2027:
• Glucophage (metformin)
• Glumetza (metformin)
• Fortamet (metformin)
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• United States
• Japan
• EU5 (Germany, France, UK, Italy, Spain)
• China
• India
• Russia
• Brazil
• This report discusses the SWOT and STEP Analysis of the global diabetes drugs market
• This report also discusses the diabetes R&D pipeline, recent approvals and summarizes anti-diabetes drug developments by Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca and others
Visiongain's study is intended for anyone requiring commercial analyses for the global diabetes drugs market. You find data, trends and predictions.
Buy our report today Global Diabetes Drugs Market 2017-2027: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others.
To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/1950/Global-Diabetes-Drugs-Market-2017-2027
Companies Mentioned in the Report:
Actavis
Alphapharm
Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)
Andromeda Biotech
Arisaph
Astellas Pharma
AstraZeneca
Bayer
Biocon
Blue Cross
Bristol-Myers Squibb
Biogen Idec
Boehringer Ingelheim
Boston Therapeutics
Chugai Pharmaceutical
Diabetes UK
DiaMedica
Diamyd Medical
Eisai
Eli Lilly
Express Scripts
Franco-Indian Pharmaceuticals
Furiex Pharmaceuticals
Genentech
Generex Biotechnology Corporation
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Human Genome Sciences
Intarcia
Janssen (subsidiary of J&J)
Johnson & Johnson (J&J)
Lupin
Kissei Pharmaceuticals
Kotobuki Pharma
Kowa
MannKind Corporation
Mascot Health Series
Merck & Co.
Merck Serono
MSD KK (Asian subsidiary of Merck & Co.)
Mylan
Novartis
Novo Nordisk
Ono Pharmaceuticals
Oramed Pharmaceuticals
Patheon
Pfizer
Ranbaxy Laboratories
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus (bought by Salix Pharmaceuticals)
Servier
Shantha Biotechnics (acquired by Sanofi)
Shionogi Pharmaceuticals
Shreya Life Sciences
Sun Pharma
Takeda
Taisho Pharmaceutical
Teva Pharmaceutical Industries
Theracos
Transdermal Specialities
Yabao Pharmaceutical
Zydus Cadila
To see a report overview please email Sara Peerun on sara.peerun@visiongain.com
Share this article